AgeX

AgeX Therapeutics is a biotechnology company that focuses on the development and commercialization of novel therapeutics targeting human aging. The company is based in Alameda, California, and was founded in 2017 as a subsidiary of BioTime. AgeX's research and development efforts are primarily focused on developing innovative cell-based therapeutics for use in regenerative medicine.

History

AgeX Therapeutics was founded in 2017 as a subsidiary of BioTime, a clinical-stage biotechnology company. The company was established with the goal of developing and commercializing novel therapeutics targeting human aging.

Research and Development

AgeX's research and development efforts are primarily focused on developing innovative cell-based therapeutics for use in regenerative medicine. The company's lead product candidates are AGEX-BAT1, AGEX-VASC1, and induced Tissue Regeneration (iTR).

AGEX-BAT1 is a cell therapy for metabolic diseases such as Type II diabetes. AGEX-VASC1 is a cell therapy for ischemic diseases. Induced Tissue Regeneration (iTR) is a drug-based approach to regenerate tissues in the body to a young state.

See Also

• BioTime
• Regenerative medicine
• Cell therapy
• Metabolic diseases
• Ischemic diseases

External Links

• Official Website

AgeX Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.

Translate to: East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski